Brixadi: FDA-Approved New Long-Acting Buprenorphine for Opioid Use Disorder
On May 23, 2023: Braeburn announced that FDA has approved Brixadi, the new long-acting formulation of buprenorphine for the opioid use disorder. Now we will…
On May 23, 2023: Braeburn announced that FDA has approved Brixadi, the new long-acting formulation of buprenorphine for the opioid use disorder. Now we will…
Naltrexone XR is an opioid antagonist, which is FDA approved for opioid use disorder. The main benefits of naltrexone-XR are: extended duration of its action…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.